Move over, Humira, there's a new mega-blockbuster in town :

There was a time not that long ago when Merck & Co. Inc.’s Keytruda (pembrolizumab), with its multiple cancer indications, was seen as the heir apparent to Humira’s title of the biggest blockbuster drug. Not anymore. That title now belongs to Novo Nordisk A/S’ semaglutide, approved as Ozempic in 2017 to treat diabetes and as Wegovy in 2021 to help with weight loss.

Related Keywords

Novo Nordisk , Merck Co , Novo Nordiska S , Semaglutide , Ozempic , Wegovy , Humira , Adalimumab , Keytruda , Merck Amp Co Inc , Pembrolizumab , Abbvie Inc , Bioworld , Regulatory , Obesity , Diabetes , Us , Biosimilar , Eli Lilly And Co , Tirzepatide , Mounjaro , Zepbound , Teva Pharmaceutical Industries Ltd , Simlandi , Gilead Sciences Inc , Drug Prices , Veklury , Analysis And Data Insight , Endocrine Metabolic , Immune ,